• Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
  

PubMed=8205547
Kotoh S., Naito S., Yokomizo A., Kumazawa J., Asakuno K., Kohno K., Kuwano M.
Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Cancer Res. 54:3248-3252(1994)

PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2
Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A., Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.
Alteration in copy numbers of genes as a mechanism for acquired drug resistance.
Cancer Res. 64:1403-1410(2004)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)